As the primary objective of the trial, Versartis will assess the safety and tolerability of a single subcutaneous dose of VRS-317 in the trial.
The company expects to recruit approximately 50 adult patients with GHD in the US and Europe.
Upon completion of this initial study, the company plans to conduct additional clinical trials in both adult and pediatric GHD patients.
Versartis founder and CEO Jeffrey Cleland said VRS-317 has the potential to be the first once monthly treatment for growth hormone deficiency with a profile appropriate for the treatment of both adult and pediatric GHD patients.
Cetero Research Medical Affairs executive vice president Mark Kipnes said a single monthly dose of VRS-317 offers a great deal of promise for improving treatment of growth hormone deficient patients.